Tislelizumab delivers improved health-related quality-of-life (HRQoL) outcomes compared with sorafenib in patients with unresectable hepatocellular carcinoma (uHCC), the latest results from the phase 3 RATIONALE-301 study show. These findings, together with the efficacy results, support the use of tislelizumab in the first-line treatment of patients with uHCC.
RATIONALE-301 (NCT03412773) randomised 674 patients with untreated uHCC 1:1 to sorafenib or tislelizumab . Previous results from this trial showed that tislelizumab was non-inferior to sorafenib for overall survival . Here, Prof. Richard Finn (University of California Los Angeles, CA, USA) outlined the data of HRQoL measures for the assessed agents.
The EORTC QLQ-C30 scale showed that patients in the sorafenib arm had a reduction from baseline in global health status/quality-of-life at cycles 4 (-5.1 vs -0.7; P=0.0037) and 6 (-5.9 vs -0.9; P=0.0022) of therapy, but that those in the tislelizumab arm did not show this deterioration. The corresponding results for physical functioning at cycle 4 (-7.7 versus -1.3; P<0.0001) and 6 (-7.2 vs -1.0; P<0.0001) displayed a benefit for tislelizumab as well. Moreover, patients in the sorafenib arm showed an increase in fatigue whereas those in the tislelizumab arm did not: cycle 4 (+9.1 vs +1.5; P<0.0001); cycle 6 (+9.8 vs +2.2; P<0.0001). The pain scores of the EORTC QLQ – HCC18 scale were comparable for the 2 arms, with an increase around +2.5 for both treatment arms at cycles 4 and 6.
After meeting its primary endpoint, data from RATIONALE-301 now demonstrated quality-of-life benefits for patients with newly diagnosed uHCC receiving tislelizumab compared with those receiving sorafenib.
- Finn RS, et al. Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population. Abstract 495, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.
- Qin S, et al. Annals of Oncology. 2022;33(7):S1402–S1403.
Copyright ©2023 Medicom Medical Publishers
« Stereotactic body radiation therapy beneficial for patients with locally advanced HCC Next Article
Improved survival following postoperative sorafenib plus TACE in HCC »
Table of Contents: ASCO GI 2023
Letter from the Editor
ASCO GI 2023 Highlights Podcast
Oesophageal and Gastric Cancer
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer
Regorafenib offers survival benefit for patients with pre-treated gastric cancer
Radiotherapy or not in locally advanced oesophageal or junctional cancer?
Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial
S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?
LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer
3-year follow-up data confirms benefits of nivolumab plus chemotherapy
Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer
Promising phase 2 results for HER-Vaxx in gastric cancer
Anal and Colorectal Cancer
IMbrave 151 missed primary endpoint in advanced BTC
Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC
Mutation-based selection to identify patients suitable for panitumumab treatment
Fucoidan associated with quality-of-life benefits in patients with rectal cancer receiving CCRT
ctDNA appears useful in monitoring patients with anal cancer undergoing CRT
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC
Does cell-free DNA influence MRD testing in post-operative colon cancer?
OPERA: surgery may be avoided with adequate therapy in rectal cancer
Can we improve total neoadjuvant therapy for rectal cancer?
Palliative radiation therapy improves hepatic pain in HCC and liver metastasis
Improved survival following postoperative sorafenib plus TACE in HCC
Quality-of-life benefits for tislelizumab in uHCC
Stereotactic body radiation therapy beneficial for patients with locally advanced HCC
SWOG 1815, first-ever phase 3 trial in BTC, fails
Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC
First-line NALIRIFOX superior to standard treatment in mPDAC
Novel approach delivers quality-of-life benefits for patients with pancreatic cancer